Aug 3 (Reuters) - Concordia International Corp CXR.TO :
* Concordia International Corp. Confirms that strategic review is ongoing and provides update on its business
* Confirmed that its review of strategic alternatives is ongoing and provided an update on its business
* Concordia has no liquidity or debt issues
* There was one formulary change affecting two products in its North America portfolio
* CVS did not reimburse for nilandron at all in past three years and has reimbursed dutoprol twice in 2016
* Concordia International Corp. Confirms that strategic review is ongoing and provides update on its business
* CVS Health (NYSE:CVS) confirmed that nilandron and dutoprol will be removed from CVS Health's formulary
* Removal of treatments from cvs health's formulary is immaterial to business Source text for Eikon: ID:nCNWQQQSBa Further company coverage: CXR.TO
(Bengaluru Newsroom: +1-646-223-8780)